Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + mFOLFIRINOX in Resectable Pancreatic Cancer
NCT04425876Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluzoparib in pancreatic adenocarcinoma (PDAC), sponsored by Hengrui. Primary endpoints: Number of participants with a dose limited toxicity at 28 Days, Maximum tolerated dose at 8 months and 2 more. Status: unknown.
02
Drugs
fluzoparib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04425876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04425876.